Anderson transition in the three dimensional symplectic universality class

We study the Anderson transition in the SU(2) model and the Ando model. We report a new precise estimate of the critical exponent for the symplectic universality class of the Anderson transition. We also report numerical estimation of the $\beta$ function.Comment: 4 pages, 5 figure

Specific Heat of the 2D Hubbard Model

Quantum Monte Carlo results for the specific heat c of the two dimensional Hubbard model are presented. At half-filling it was observed that $c \sim T^2$ at very low temperatures. Two distinct features were also identified: a low temperature peak related to the spin degrees of freedom and a higher temperature broad peak related to the charge degrees of freedom. Away from half-filling the spin induced feature slowly disappears as a function of hole doping while the charge feature moves to lower temperature. A comparison with experimental results for the high temperature cuprates is discussed.Comment: 6 pages, RevTex, 11 figures embedded in the text, Submitted to Phys. Rev.

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

Background:: A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC). Patients and methods:: CRC patients not pretreated with palliative chemotherapy, with performance status ≤1 and adequate haematological, kidney and liver function, were eligible. Treatment consisted in weekly 24-h infusion 5-FU (2300 mg/m2)/LV (30 mg) and alternating OHP (70-85 mg/m2, days 1 and 15) and CPT-11 (80-140 mg/m2, days 8 and 22) repeated every 5 weeks. OHP and CPT-11 were escalated in cohorts of three to six patients. Results:: Thirty patients received a median of five cycles. Dose-limiting toxicity occurred at dose level 3, and the recommended dose was OHP 70 mg/m2, CPT-11 100 mg/m2, LV 30 mg and 5-FU 2300 mg/m2/24 h. Grade ≥3 toxicities were diarrhea 23%, neutropenia 20%, fatigue 7%, and neurologic 7%. Two febrile neutropenia episodes (one fatal) were recorded. Among 28 patients with measurable disease (90%), we observed two complete and 20 partial responses; overall RR was 78% (95% CI, 59% to 92%). Median time to progression and overall survival were 9.5 and 25.4 months, respectively. Seven patients underwent liver metastases resection. Conclusion:: OCFL is an overall well tolerated regimen with very high efficacy, which makes it most suitable for tumour control before surgery of metastatic diseas

Retargeted adenoviruses for radiation-guided gene delivery

The combination of radiation with radiosensitizing gene delivery or oncolytic viruses promises to provide an advantage that could improve the therapeutic results for glioblastoma. X-rays can induce significant molecular changes in cancer cells. We isolated the GIRLRG peptide that binds to radiation-inducible 78 kDa glucose-regulated protein (GRP78), which is overexpressed on the plasma membranes of irradiated cancer cells and tumor-associated microvascular endothelial cells. The goal of our study was to improve tumor-specific adenovirus-mediated gene delivery by selectively targeting the adenovirus binding to this radiation-inducible protein. We employed an adenoviral fiber replacement approach to conduct a study of the targeting utility of GRP78-binding peptide. We have developed fiber-modified adenoviruses encoding the GRP78-binding peptide inserted into the fiber-fibritin. We have evaluated the reporter gene expression of fiber-modified adenoviruses in vitro using a panel of glioma cells and a human D54MG tumor xenograft model. The obtained results demonstrated that employment of the GRP78-binding peptide resulted in increased gene expression in irradiated tumors following infection with fiber-modified adenoviruses, compared with untreated tumor cells. These studies demonstrate the feasibility of adenoviral retargeting using the GRP78-binding peptide that selectively recognizes tumor cells responding to radiation treatment

Evidence for Surface Andreev Bound states in Cuprate Superconductors from Penetration Depth Measurements

Tunneling and theoretical studies have suggested that Andreev bound states form at certain surfaces of unconventional superconductors. Through studies of the temperature and field dependence of the in-plane magnetic penetration depth lambda_ab at low temperature, we have found strong evidence for the presence of these states in clean single crystal YBCO and BSCCO. Crystals cut to expose a [110] interface show a strong upturn in lambda_ab at around 7K, when the field is oriented so that the supercurrents flow around this surface. In YBCO this upturn is completely suppressed by a field of ~0.1 T.Comment: 4 pages 2 column revtex + 4 postscript figures. Submitted to PR

Relation between Energy Level Statistics and Phase Transition and its Application to the Anderson Model

A general method to describe a second-order phase transition is discussed. It starts from the energy level statistics and uses of finite-size scaling. It is applied to the metal-insulator transition (MIT) in the Anderson model of localization, evaluating the cumulative level-spacing distribution as well as the Dyson-Metha statistics. The critical disorder $W_{c}=16.5$ and the critical exponent $\nu=1.34$ are computed.Comment: 9 pages, Latex, 6 PostScript figures in uuencoded compressed tar file are appende

Anomalous Quantum Diffusion at the Superfluid-Insulator Transition

We consider the problem of the superconductor-insulator transition in the presence of disorder, assuming that the fermionic degrees of freedom can be ignored so that the problem reduces to one of Cooper pair localization. Weak disorder drives the critical behavior away from the pure critical point, initially towards a diffusive fixed point. We consider the effects of Coulomb interactions and quantum interference at this diffusive fixed point. Coulomb interactions enhance the conductivity, in contrast to the situation for fermions, essentially because the exchange interaction is opposite in sign. The interaction-driven enhancement of the conductivity is larger than the weak-localization suppression, so the system scales to a perfect conductor. Thus, it is a consistent possibility for the critical resistivity at the superconductor-insulator transition to be zero, but this value is only approached logarithmically. We determine the values of the critical exponents $\eta,z,\nu$ and comment on possible implications for the interpretation of experiments

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients

Background: Exclusive liver metastases occur in up to 40% of patients with uveal melanoma associated with a median survival of 2-7 months. Single agent response rates with commonly available chemotherapy are below 10%. We have investigated the use of fotemustine via direct intra-arterial hepatic (i.a.h.) administration in patients with uveal melanoma metastases. Patients and methods: A total of 101 patients from seven centers were treated with i.a.h. fotemustine, administered intra-arterially weekly for a 4-week induction period, and then as a maintenance treatment every 3 weeks until disease progression, unacceptable toxicity or patient refusal. Results: A median of eight fotemustine infusions per patient were delivered (range 1-26). Catheter related complications occurred in 23% of patients; however, this required treatment discontinuation in only 10% of the patients. The overall response rate was 36% with a median overall survival of 15 months and a 2-year survival rate of 29%. LDH, time between diagnosis and treatment start and gender were significant predictors of survival. Conclusions: Locoregional treatment with fotemustine is well tolerated and seems to improve outcome of this poor prognosis patient population. Median survival rates are among the longest reported and one-third of the patients are still alive at 2 year

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly established chemotherapeutic regimens and the aim of treatment is palliation with improvement in the quality of life. Patients and methods: We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITI] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) ≥ 70. One hundred twenty-eight patients were histologically confirmed with GBM or gliosarcoma (GS) by independent central review. Chemotherapy-naïve patients were treated with temozolomide 200 mg/m2/day2/day orally for the first five days of a 28-day cycle. Patients previously treated with nitrosourea- containing adjuvant chemotherapy received 150 mg/m2/day for the first five days of a 28-day cycle. In the absence of grade 3 or 4 toxicity, patients on the 150 mg/m2 dose schedule were eligible for a 200 mg/m2 dose on the next cycle. Results: The primary endpoint was six-month progression-free survival assessed with strict radiological and clinical criteria. Secondary endpoints included radiological response and Health-related Quality of Life (HQL). Progression-free survival at six months was 18% (95% confidence interval (CI): 11%-26%) for the eligible-histology population. Median progression-free survival and median overall survival were 2.1 months and 5.4 months, respectively. The six-month survival rate was 46%. The objective response rate (complete response and partial response) determined by independent central review of gadolinium-enhanced magnetic resonance imaging (MRI) scans was 8% for both the ITT and eligible-histology populations, with an additional 43%;A and 45% of patients, respectively, having stable disease (SD). Objectively assessed response and maintenance of a progression-free status were both associated with HQL benefits (characterized by improvements over baseline in HQL domains). Temozolomide had an acceptable safety profile, with only 9% of therapy cycles requiring a dose reduction due to thrombocytopenia. There was no evidence of cumulative hematologic toxicity. Conclusions: Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM. The use of this drug should be explored further in an adjuvant setting and in combination with other agent